Clinical Trials Browser

Phase 1/2 × INDUSTRY × imisopasem manganese × Clear all

NCT00033956 2005-06-24

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

Phase 1/2 Suspended

DermatologicGenitourinary

Carcinoma, Renal Cell, Hypotension, Melanoma